Stock Weather AIBiotechnologyClinical Stage Therapeutics
Spyre Therapeutics – 2025-12-03 - increase Confidence 7/10
Negative free cash flow offset by strong analyst consensus and recent corporate repositioning in IBD space suggests near-term upside on sentiment-driven momentum.